Skip to Main Content

Amarin (AMRN) pre-announced record quarterly sales of its heart drug Vascepa on Tuesday and raised its financial guidance for the remainder of the year, citing strong patient demand for the drug, derived from fish oil, now that it has been shown to significantly lower the risk of death and other adverse cardiovascular events.

The Bedminster, New Jersey-based drug maker is also doubling the size of its commercial salesforce to prepare for the highly expected expansion of Vascepa’s label by the Food and Drug Administration in late September, the company said. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I take Vascepa twice daily. My medical professional prescribed this for me several years ago. Of course my insurance will not pay for me to take it. I Have been able to get samples from my Doctor thank him. I can’t believe how much this medication has helped me with no side effects. Just great.

  • Excellent article Mr. Feuerstein. My belief is that you were right when
    you indicated that AMRN should be acquired by a BP with a strong
    Cardiovascular sales arm. I would expect Pfizer, Novartis, Amgen,
    and Johnson & Johnson to be the best candidates to acquire Amarin.
    However, would not count out GILD, LLY, or NVO. Just a matter of time.

Comments are closed.